CRIACommunity Research Initiative on AIDS

1995 Annual Report

MESSAGE FROM ROSS BLECKNER, PRESIDENT
1995 was a period defined by change, growth and challenge for the Community Research Initiative on AIDS (CRIA).

We began the year with a new Executive Director, J Daniel Stricker, who joined us in January 1995 after a five-year tenure as Deputy Executive Director at God's Love We Deliver. We are delighted to have him on staff and especially pleased that his predecessor and CRIA co-founder, Marisa Cardinale, has continued to share with us the inexhaustible energy and expertise with which she led CRIA for 3 years, in her new capacity as a member of the Board of Directors.

All of our 1995 research and educational activities, as well as the individual and institutional funders who made them possible, are described on the following pages. We have also taken the opportunity in this, CRIA's debut annual report, to share with you our background - how and why the agency came into being - and to acquaint you with the rigorous nature of our work by outlining the multifaceted stages involved in conducting a clinical trial.

CRIA has come a long way since its founding almost five years ago. Unfortunately, it is all too clear that we have a long way to go. According to the Centers for Disease Control (CDC), as of June of 1995, for every American who dies of AIDS-related disease, another becomes infected with the HIV virus. One need only consider this statistic to comprehend the urgency of our work and the significance of each and every one of the donors who allow us to move forward. Your support will enable us to continue to fulfill the mission upon which CRIA was founded: to conduct rapid and cost-effective research, with the highest scientific standards, on promising AIDS treatments in time to help those who are already infected.

Ross Bleckner President of the Board of Directors

MISSION STATEMENT/ORGANIZATIONAL BACKGROUND

CRIA was incorporated in December 1991, by a group of physicians, activists, and people living with AIDS who were discouraged by the restraints and red tape debilitating government and academic AIDS research efforts. Under the leadership of the medical community's foremost AIDS practitioners and researchers, the group set out to create an agency which would bring activism to the ever-urgent task of studying AIDS-related illness and treatments.

CRIA's status - as an independent, not-for-profit, research organization - uniquely qualifies us to evaluate drugs and treatments that for-profit facilities might otherwise lack the financial incentive to explore. Indeed, the fact that our work is driven solely by the daily, real-life, medical needs of PLWAs, rather than by monetary return, is exactly what positions CRIA on the front lines of the battle against AIDS. When late breaking information is released, we are able to take advantage of it, incorporating it into our research initiatives at a much faster pace than profit-driven concerns. As a result, we can complete a preliminary study of a new drug within months - rather than years.

While most research projects require millions of dollars to underwrite, CRIA's studies generally run between $35,000 and $250,000. And, although our resources are limited to a small staff and moderate operating costs (in 1995, CRIA had nine employees and an annual budget that barely exceeded $1,000,000), our efforts have far-reaching impact, affecting the health and lives of PLWAs worldwide. Most recently, on March 1st, 1996, ritonavir - the protease inhibitor which CRIA has been studying in collaboration with Abbott Laboratories - was granted full FDA approval for use by PLWAs with advanced-stage disease. CRIA research has also led to FDA approval of two other critical AIDS drugs: rifabutin, which prevents MAC (Mycobacterium avium complex), a deadly disease that is the leading cause of AIDS-related wasting, and Marinol, a leading appetite stimulant.

CONDUCTING A CLINICAL TRIAL: AN OVERVIEW

Formal medical research - whether it involves a promising new treatment, a new use for an existing treatment or the study of a disease - is always a rigorous process, and one which must comply with the Department of Health and Human Services' regulations for the protection of human research subjects.

To ensure that CRIA's initiatives are conducted as meticulously and as efficiently as possible, we have recruited the finest minds in the AIDS arena - doctors and activists, scientists and researchers - who help to assure the scientific integrity of all our research endeavors. Equally important is the input of the trial participants who are, themselves, living with the day-to-day reality of HIV/AIDS.

These are the basic activities involved in conducting a clinical research trial from start to finish. The first step of any research project is to identify The Question to be answered. Once the question - which is, in fact, the premise for the study - has been determined, the researchers must contemplate the best way to approach its answer. For example, it's not enough just to give people a new drug and then observe them. Reliable research must take place within an organized scientific framework. One has to be aware of what is already known about the drug, what it is hoped that the drug will do, why it is thought to be promising, what toxicities are expected, and how extensive the effects of the drug might be.

These considerations are set forth in a Concept Sheet which is submitted for comprehensive review to CRIA's Scientific Advisory Committee (SAC), a group of leading AIDS researchers who validate that any approved study plan meets the highest scientific standards.

With SAC approval, the concept sheet is ready to move onto a more evolved stage: The Protocol. The protocol is a blue print of the concept sheet which details:

The completed protocol is submitted to the SAC for final scientific review and to our Institutional Review Board (IRB) for ethical review. The IRB is responsible for ensuring that studies respect the rights of the participants and that the investigators have taken the necessary precautions to guarantee their safety and well being.

As soon as potential patients are identified, Study Implementation begins. CRIA's clinical staff carefully explain the study's informed consent which must be signed by participants indicating that they have been apprised of all trial requirements and possible risks and benefits, and agree to participate. Applicants are then carefully screened to determine whether they fulfill the inclusion criteria outlined in the protocol. They are then "officially" enrolled and ready to begin treatment.

Treatment may involve administering a drug or medical therapy (if it is a clinical trial) or conducting comprehensive observation of patients with a specific opportunistic infection (if the study is informational). A clinical trial may be "open-label" where all participants receive the drug, or "blinded" where half the participants receive placebo. At the end of many "blinded" clinical trials, all participants - even those on placebo - are given access to the drug being studied.

Throughout the course of the trial, the study participants are required to make regular visits to the trial site where their medical status is closely monitored, especially at the beginning of the study when the impact of the drug has yet to be determined.

During the study, the IRB maintains an active supervisory role, ensuring that the study is explained thoroughly and repeatedly to all participants, and that any new information about toxicities is disseminated to the enrollees as soon as possible.

Furthermore, CRIA and the IRB periodically review information from the study to confirm that its continuation is a good idea. If, for example, a toxicity is identified which outweighs the benefits anticipated by the drug in question or, if the initial findings indicate that the drug is significantly less effective than the comparison treatment, we may decide to interrupt or halt the study.

When all of the study participants have completed the study, the data is submitted for Analysis by a statistician who determines whether the findings are statistically significant in relation to the initial question.

Finally, investigators will review the statistician's report and write up the results for Publication in a scientific journal. This is how study results are disseminated to allow patients and physicians to incorporate new findings into the treatment of AIDS.

MESSAGE FROM THE EXECUTIVE DIRECTOR

When I was first interviewing with CRIA for the position of Executive Director, I spoke with Board Member, Kiki Mason, who has been living with AIDS since 1990, about the significance of the agency's work.

During 1995, I had many firsthand opportunities to witness the reasons why CRIA is so important - not only to Kiki, but also to countless other people living with AIDS (PLWAs) like him. Perhaps one of our most indispensable features is that we offer PLWAs - a population that does not have the luxury of waiting around for effective treatments to be approved - the invaluable and, oftentimes only, opportunity to access promising new drugs while they are still in development. For this reason, many PLWAs view CRIA as their last, best chance to obtain the drug that just may be the one to save their lives.

As a community-based, not-for-profit organization, CRIA's primary obligation is to our community - the ever-growing number of men, women, and children living with the day-to-day reality of AIDS. This reality poses questions that range from the medical (e.g., "What is best and safest drug regimen for my condition?") to the more functional (e.g., "Which type of nutritional supplement will really help me to maintain my weight and won't affect my eating/digestion?" and "Does exercise really have significant benefits for PLWAs and, if so, what kind and how often?") And, although the latter concerns hold little financial promise (and thus, little interest) for for-profit research organizations, their answers are of upmost importance to the PLWA community and therefore, merit investigation.

CRIA has always been committed to exploring all manner of AIDS-related questions - especially those that would otherwise go unanswered. We are currently involved in more studies than we have ever been at any time in our five year history (during January 1996, CRIA launched four new research trials), and we plan on further diversifying our agenda as the year continues. In these challenging times, we are all the more aware of - and grateful for - the generosity of our donors and volunteers who enable us to move beyond AIDS-related questions and speculations towards potentially lifesaving answers and understanding. CRIA's critical efforts - which bring us closer to finding a cure for AIDS - continue only with your assistance.

J Daniel Stricker Executive Director

In 1995, CRIA pursued an extremely active and challenging research and educational agenda, the components of which are outlined below.

1995 Research Initiatives

Protease Inhibitor/Ritonavir
One of CRIA's most exciting research activities during 1995 was our cooperative study with Abbott Laboratories of ritonavir, a member of the new and very promising class of "protease inhibitor" drugs which block HIV reproduction. After infecting new cells, HIV produces long strands of proteins which must be cut into smaller proteins in order to assemble new viruses. This cutting is accomplished by an enzyme called the HIV Protease. By obstructing the activity of the HIV Protease, ritonavir may prevent assembly of new viruses. Other anti-HIV drugs, such as AZT, ddI, ddC and d4T, work at a different stage of the viral reproductive cycle.

The Abbott/CRIA study compared ritonavir to placebo in patients with less than 100 T-cells who had used other antiviral treatments. And, although many researchers have believed that it might be impossible to restore immunity in people with late stage AIDS, our initial findings suggested that ritonavir may reduce HIV levels and increase T-cell levels - even in patients whose immune systems have already been ravaged by AIDS.

Based on these findings, the FDA granted ritonavir "split approval" on March 1st, 1996. For patients with advanced stage AIDS, the drug may be sold with full approval. However, for patients in the early stages of infection, the drug received a conditional go-ahead called "accelerated approval" which allows the drug to be marketed for this constituency, but requires that clinical tests be conducted to determine whether the drug's early promise, as measured by the Abbott/CRIA trial, translates into better health and extended lives for PLWAs in the long run. To this end, CRIA will continue its partnership with Abbott and will begin a new clinical trial to study the effects of long-term usage of ritonavir in the spring of 1996.

Cyclophosphamide
In November, CRIA collaborated with Dr. Joseph Chuba of N.Y.U. and Dr. Yoritaro Inada of St. Luke's-Roosevelt Hospital to launch the first independent AIDS treatment trial of cyclophosphamide (CY), a drug that is used in cancer chemotherapy. In high doses, CY has the ability to kill proliferating cells, making it useful in preventing tumor growth. In very low doses, however, it has well-documented immuno-modulatory properties, and may be able to reduce the activity of B-cells which are abnormally overactive in PLWAs, and are responsible for producing large quantities of immunoglobulins which are believed to negatively impact health. The goal of CRIA's cyclophosphamide study is to determine whether the drug is, indeed, effective in slowing B-cell activity among PLWAs and, if so, to identify a safe dose that does not adversely affect T-cell counts and white blood cells.

Methotrexate
CRIA also became a site for a study, organized by the National Institutes of Health, of methotrexate, an immunosuppressive drug used most commonly for people with cancer and other autoimmune diseases. The study, which is currently enrolling, will evaluate the safety of methotrexate in HIV+ people with 350+ T-cells and determine whether it can inhibit immune activation, which is believed to hasten HIV reproduction.

Testosterone
At the end of 1995, CRIA began a pilot study, in conjunction with Dr. Judith Rabkin of Columbia University in New York City, to evaluate the effects of testosterone injections on the muscle mass/body composition, energy levels, and psychological well-being of HIV+ men. About 50% of HIV+ men with CD counts below 200 experience low testosterone levels, the repercussions of which may include weight loss, loss of lean muscle mass, decrease in sexual interest/function, and depression. Although testosterone replacement is commonly used to treat hormonal deficiencies in HIV+ men, the efficacy of employing this approach to treat AIDS-related wasting has never been thoroughly investigated.

CRIA's pilot study is exploring the possible benefits of testosterone injections among 30 HIV+ adult males with CD4 cell counts less than 400, abnormally low testosterone levels, and signs of weight loss or loss of lean body mass. All trial participants are receiving testosterone injections for 12 weeks, after which they will be randomly assigned to a six-week regimen of continued testosterone injections or placebo injections. The purpose of the latter phase is to determine whether the gains achieved during the first 12 weeks are more likely to be sustained by continuing or ceasing the testosterone injections.

It is hoped that testosterone injections will prove beneficial to men with HIV, not only by increasing lean body mass, but also by improving their mood and sexual interest/function, and restoring their overall sense of well-being. If so, this treatment could be a promising and much more affordable alternative to the Human Growth Hormone (HGH), an experimental and very costly therapy, which may increase lean body mass. It may also help to decrease the prevalence of antidepressant medications which are used increasingly by PLWAs, and known to produce adverse side effects.

CRIA also continued work on a number of research studies/projects which were launched prior to 1995.

Kaposi's sarcoma (KS)
Although the mainstay of CRIA's research focuses on evaluating promising AIDS therapies, we are also committed to pursuing information to facilitate the progress against AIDS and its related opportunistic diseases. A prime example of our work in this area is the Kaposi's sarcoma (KS) Pathogenesis Project which we initiated in 1994 and continued to move forward with in 1995. This project, which began as a collaboration with Dr. Barbara Ensoli of the Laboratory of Tumor Cell Biology at the National Cancer Institute, is the first systematic investigation of KS pathogenesis. Our goal is to determine patterns in the cause, growth and spread of the lesions associated with KS, and, in doing so, obtain information that will facilitate the development of safer and more effective treatments for this dreaded opportunistic infection.

CRIA's KS research staff dedicated a great deal of 1995 to working with our project team of community physicians to identify, enroll, and collect samples from eligible study participants. Because project participation is limited only to PLWAs with KS who have not received treatment (a population which is extremely scarce since most PLWAs with KS begin treatment immediately upon diagnosis), enrollment has been a somewhat arduous process. However, by adding new doctors to our project team to assist with recruitment and referrals, and by contacting alternative health providers (whose patients are less likely to have been treated with western medicine), we have been able to enroll enough patients to provide Dr. Ensoli with the necessary tissue, urine and blood samples for her analysis. Her preliminary results will be presented towards the end of 1996.

One of the qualities that differentiates CRIA from a larger, more bureaucratic for-profit research groups is our ability to modify a study or a protocol, mid-course, by encorporating newly-released information that could add to the validity of our findings. This enabled us to take advantage of the ground breaking discovery of the "KS-associated herpes virus" (HHV-8) which was announced in the spring of 1995 by Drs. Yuan Chang and Patrick Moore, researchers from Columbia Presbyterian Hospital in New York City.

As an offshoot to our work with Dr. Ensoli, CRIA joined forces with the Chang/Moore team and, since September, has served as the sole source of clinical samples for their continued investigation regarding the possible role of HHV-8 in the KS pathenogenisis. This has not only allowed us to involve a number of the PLWAs who screened out of the Ensoli project because of their histories of chemotherapy, but also to jumpstart the Chang/Moore team's continued research which had been stalled due to a paucity of samples.

Aspirin/Trilisate
CRIA halted its study of the anti-HIV properties of high-dose aspirin in early 1995, when trial participants taking high-dose aspirin exhibited blood and liver abnormalities. This information -- which presented concerns about the possible toxicity of such high doses -- was immediately disseminated nationally to alert PLWAs who had started this therapy on their own.

Because CRIA's preliminary analysis also revealed evidence that HIV levels may have declined more in the patients taking aspirin than those taking placebo, we were encouraged to redesign the original study using Trilisate, a chemical related to, but believed to be less toxic than, its cousin, aspirin. However, before revising the trial, we first implemented a small, open label pilot study to confirm that similar toxicities would not recur. Although this pilot study did, indeed, find that Trilisate avoided the anemia problem seen with aspirin, many of the study participants experienced abnormalities in liver function which dissuaded CRIA from pursuing a long-term, double-blinded Trilisate protocol.

Delavirdine and Nevirapine
CRIA also continued the cooperative efforts that we began in late 1994 with two leading pharmaceutical companies to evaluate the effects of Delavirdine and Nevirapine, promising, experimental anti-HIV drugs which may slow the progression of HIV disease. The two-year, double-blinded trial of Delavirdine, which we are conducting with Pharmacia & Upjohn, Inc., is comparing three Delavirdine/AZT combinations with an AZT/3TC combination. 1995 also marked the completion of the double-blinded phase of Boehringer-lngleheim Pharmaceutical, Inc.'s collaborative study with CRIA comparing Nevirapine and placebo. All study participants were subsequently rolled over into a six-month open-label study.

1995 Educational Activities

Educational Forums
At CRIA, we understand that providing PLWAs with accurate information is the first step towards empowering them to take an active role in their own treatment. To assure that the latest facts and figures about AIDS research and medications are easily accessible and easily understandable, CRIA - in cooperation with Gay Men's Health Crisis (GMHC) and the Treatment Action Group (TAG) - sponsors monthly Educational Forums which are free of charge and open to the general public. In 1995, these forums, which feature presentations by leading AIDS physicians and researchers on a wide array of ground breaking issues, included:

These forums attracted audiences ranging from 100 to 400 individuals. In 1995, CRIA absorbed the cost of providing interpreters so that the forums would be accessible to the hearing impaired.

CRIA Update
We also redesigned CRIA Update, our quarterly newsletter, increasing its educational content and improving readability. Each issue of the newly-formatted publication includes 12 pages (increased from four) of articles and information dedicated to one main topic - oftentimes corresponding with the issues discussed in the educational forums. It also includes reviews of significant research and treatment activities on the international front. 1995 issues of CRIA Update featured in-depth coverage of Kaposi's sarcoma (KS), AIDS-related wasting and weight loss, and recent advances in antiviral medications.

Development
CRIA is completely dependent upon the generosity of private sector supporters who sustain our challenging research agenda with their resources, time and talents.

Some people think that a donation of ten or twenty dollars is not enough to make a real difference in the fight against AIDS. This is certainly not the case at CRIA. In 1995, individual donations totaled nearly $800,000, over 60% of our total 1995 revenue. These monies were supplemented by approximately $540,000 in corporate and foundation grants from long-time friends like The J. M. Kaplan Fund, the Royal S. Marks Foundation Fund, and the David Geffen Foundation, as well as from first-time funding partners, including the Philip Morris Companies Inc., The Charles Engelhard Foundation, and The Red Hot Organization. (A comprehensive list of our 1995 $1,000+ individual and institutional donors appears on page 11.)

Special events have always been key to CRIA's annual fundraising efforts, and 1995 was no exception. Throughout the year, we offered the public the opportunity to advance AIDS research and have a good time while doing so. Through a wide array of benefits, which included our annual Hamptons Barbecue and Unframed Art Sale, and the Bid for Life auction at Sotheby's, we were able to raise over $600,000 to underwrite CRIA's research and educational activities. We are truly grateful to all of our event sponsors, underwriters, and supporters who helped to make this possible.

Volunteers are also critical to CRIA's ongoing activities, and we are extremely fortunate to have access to one of the most committed corps imaginable. Our Board, Oversight, and Advisory Committees include some of the finest minds in the AIDS arena - professionals who share our founding mission and donate their time and expertise to help us fulfill it. Equally important are the individuals who come to our office everyday to provide CRIA's staff with the clerical support that allows us operate efficiently with minimal overhead costs.

Administration/Finance
1995 saw a number of important administrative and financial changes at CRIA- all geared towards maximizing the agency's efficacy in order to enhance our research and educational activities. We revisited our mission, reassessed our long and short term priorities, streamlined personnel responsibilities and whenever possible, tightened our budget lines. The agency emerged from this process with a solidly defined infrastructure, strong financial and operational systems, and a sense of renewed energy.

We also effected a number of physical changes, the most significant of which included enhancing CRIA's office space to make it more pleasant and personal for visiting patients, and updating our office equipment to expedite our diverse administrative operations. By renovating our office space, we were able to add two new examining rooms and thus, increase the number of patients who can be seen privately. And, by upgrading and networking CRIA's in-house computer system, we were able to make significant strides in our ability to centralize, integrate, and modernize the methods with which we conduct our day-to-day activities. With our new capabilities, we can now consider going "on-line" to disseminate information about our research trials and educational activities over the Internet.

Message from the Treasurer
Fiscal year 1995 needed to be a year of financial stabilization for CRIA, and I am pleased to report that we were successful in accomplishing this goal.

After ending the last two fiscal years with deficits, we were able to double our 1994 revenue, while restricting our expense growth to a mere 11% - circumstances which allowed us to complete 1995 with over $400,000 in excess revenue over expenses. The Board of Directors allocated $250,000 of these monies to a cash reserve fund which will insure CRIA's solvency during the inevitable funding fluctuations which impact all not-for-profit organizations. The remaining monies allowed us to begin 1996 by launching four exciting new research trials - something that would not have been possible without first building a solid financial base. Our cash reserve assures that we will not have to halt a clinical trial due to insufficient funds. We were pleased to end fiscal year 1995 by tripling the agency's net worth.

The New York Philanthropic Advisory Council (NYPAS), an independent agency which reviews charities, states that it is very common for young organizations - such as CRIA - to spend 50% of their revenue on supporting services, and that, with age, this percentage should shift with the majority of revenue directed to program services. This is exactly what we are seeing at CRIA. In 1995, we were able to increase the percentage allocated to our research and education services from 54% to 68%, while reducing administrative and fundraising costs from 46% to 32%. This is a very important accomplishment - and a direction in which we will continue to move in 1996.

While we are extremely encouraged by CRIA's financial progress during the past year, an agency of our small size and limited staff resources faces an ongoing uphill battle to maintain the steady flow of research dollars that launching clinical trials requires. Whereas hospital and academic clinical trial centers depend upon their parent institutions to underwrite the staff salaries and expenses not covered by specific research grants, CRIA's ground breaking agenda depends entirely upon private sector dollars - and the generosity of individuals and institutions that appreciate the need to support AIDS research at the community-based level.

If you are already among this group, we thank you - and invite you to reaffirm your commitment to our critical efforts. If not, we urge you to join CRIA in our search for new safe and effective treatments for the ever-growing number of people living with AIDS. We can not do it without you.

Every budgeted line item - from office supplies to personnel salaries to meal costs - has been scrutinized, evaluated, and, whenever possible, tightened. Non-programmatic costs have been reduced significantly, with staff positions streamlined, upgraded and, in certain cases, eliminated. The end result is a fiscally prudent organization with a solidly defined infrastructure and an effective, resourceful sound business strategy

Equally significant is the fact that we were able to reduce our administrative and fundraising costs from 46% to 32%, while building our programmatic expenses from 54% to 68% This is a very important change - and a direction in which we will continue to move in 1996.

George Stathakis Treasurer, Board of Directors

Independent Auditors' Report

Certified Public Accountants, LLP 300 East 42nd Street New York, NY 10017 212-697-2299 fax:212-949-1768

We have audited the accompanying statements of financial position of Community Research Initiative on AIDS, Inc. (a not-for-profit corporation), as of December 31, 1995 and 1994, and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Organization's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Community Research Initiative on AIDS, Inc. as of December 31, 1995 and 1994, and the changes in its net assets and its cash flows for the years then ended in conformity with generally accepted accounting principles.

As discussed in Note 1 to the financial statements, in 1995 the Organization changed its method of accounting for contributions and its method of financial reporting and financial statement presentation.

New York, New York February 8, 1996

COMMUNITY RESEARCH INITIATIVE ON AIDS, INC. STATEMENTS OF FINANCIAL POSITION DECEMBER 31, 1995 and 1994 COMMUNITY RESEARCH INITIATIVE ON AIDS, INC.
Notes To Financial Statements December 31, 1995 and 1994

Note 1 - Summary of Significant Accounting Policies

Note 2- Restrictions on Assets

Although space limitations require that we limit our 1995 listing to donors who participated at the $1,000 level and above, we would like to reiterate our appreciation to everyone who supported our work during the past year.

Mr. Walter Allwine
AmFAR
Anonymous
Mr. Melvie Arslanian
Barneys New York
Mr. Allen J. Beeber
Mr. Leonard Bellinger
Ms. Carolyn Benitez
Mr. Joey Berlin
The Bills Foundation
Mr. Ross Bleckner
Gay Block & Malka Drucker Philanthopic Fund
Mr. and Mrs. Martin Blinder
Estate of Ethan Bogen
Ms. Kyrle Boldt
Mr. and Mrs. Nuno Brandolini
Mr. H. J. Brown
Buhl Family Foundation
Estate of Jeffrey L. Carples
Ms. Helena Christensen
Mr. Brian Clarke
Mr. Bob Colacello
Mr. Lafayette Compton
Computer Associates Ms.
Cydney Cort
Mr. Dionigi Cossu and Ms. Rebecca Cort
Dr. James E. Cottrell and Mr. Joseph F. Lovett
The Cowles Charitable Trust
Mr. Charles Cowles
Mr. and Mrs. William D'Amico
Dr. Yael Danieli
Mr. Stephan de Kwiatkowski
Mr. David De Sanctis
Mr. Glenn Dranoff
Mr. Ofer Drori
Mr. Peter Dunham
Mr. Peter J. Edge
Ms. Gail Elliot
The Charles Engelhard Foundation
Mr. Thomas Erben
Entertainment Weekly
Mr. Ted Field
Dr. Laurent Fischer
Mr. Eric Fischl
Mr. J. A. Forde
Mr. Edward Friedlander
The David Geffen Foundation
Mr. Albert A. Geiger
Mr. and Mrs. Robert Gersh
Mr. Stephane Gerson and Ms. Alison B. Gerson
Ms. Joy Glass and Mr. Richard Milazzo
Mr. Michael Goff
Mr. Robert F. Goldrich
Mr. Rick Goldstein
Ms. Cristina Greeven
Mr. Daniel Grey
Mr. Patrick Guadagno
Ms. Agnes Gund and Mr. Daniel Shapiro
Mr. Peter Halley
Mr. Brian Hanna
Mr. Henry Hay
Mr. Tom Healy and Mr. Fred Hochberg
Mr. Vincent Hemphill
Ms. Wilma Hockett
Mr. Stephen Holden
Mr. Dennis Hopper
Mr. George Horner
Jazz For AIDS Foundation
The J.M. Kaplan Fund
Ms. Jennifer Kaplan
Mr. Dean Kauffman
Mr. Christos Kavathas
Mr. Jordan S. Kerner
Mr. James W. Kerr Mr. and Mrs. Calvin Klein
Ms. Anja Kneller
Mr. David J. Knight and Mr. Joseph Colagreco
Mr. Ronny Kropveld
Ms. Barbara Kruger
Mr. Michael Kulp
Mr. Sal Lafata and Mr. Stuart Caldwell
Ms. Angela Lange
Mr. and Mrs. Paul Laster
Mr. Philippe Laub
Mr. Chad Leat
Mrs. Fernand Leval
Mr. Warren Lichtenstein
Lifebeat Inc.
Ms. Monica Lynch
Mr. Christopher Makos
Ms. Fern Mallis
Mr. Alvaro Martinez-Fonts
Mr. Garrison McDavid Bruce & Nancy McGaw Foundation
Rev. Richard McKeon
Mr. Terrence McNally and Mr. Gary Bonasorte
Mr. Charles Milite
Mr. Keith Miller
Mr. & Mrs. Richard Mishaan
Mr. David Mogull
Mr. Frank Moore
Mr. Ahmed M. Morsi
Mr. Michael Navon and Ms. Smadar Bandman
Mr. Ralf C. Nemec
Mrs. Sheila Newmazee
Mr. and Mrs. Geri Obler
The Odeon
Mr. Harold M. Olshansky
Mrs. Noriko Onoda
Mr. Steve Paul
Philip Morris Companies, Inc.
Mr. Sebastian Piras
Mr. Luis Plaza
Mr. Giora Rachminov
Mr. Marcos E. Rada
Red Hot Organization
Robert Cutarella Entertainment
Rodgers Family Foundation
Mr. Alan Rogers
Mr. Sy Ross
Ms. Kathy Ruttenberg
Mr. Michael Safdiah
Mr. David Salle
Mr. Scott G. Sanders
Mr. Ken Schechter
Mr. Julian Schnabel
Joseph E. Seagrams & Sons, Inc.
Mr .and Mrs. Eric Seid
Mr. David Seidner
Ms. Bippy Siegal
Sotheby's
Mr. Stephen Snyder
Stadtlander Drug Co.
Cathay Sterling
Mr. Jay Sternberg
Mr. J Daniel Stricker
Sydney R. Rosenau Foundation
Mr. Philip Taaffe
Mr. Dominic Taglialatella
Mr. Donald Taglialatella
The H. van Ameringen Foundation
Video Industry
AIDS Action Committee
Mr. Herbert Vogel
Mr. Dieter von Graffenried
Ms. Lynn Wagenknecht
Mr. Alan Wanzenberg
Mr. Eric Warner
Mr. and Mrs. Lillian Weiss
Mr. Gregory B. Williams
Mr. Terry Winters
Mr. Robert Woolley
Mr. Gamblin Yann
Mr. Alexis P. Zoullas
Mr. and Mrs. Sophocles Zoullas

I'm H.I.V. positive
It doesn't have to be negative.

David Seidner
Photographer		 I'm H.I.V. positive.
I'd rather not be.

Larry Kramer
Writer, Activist
I'm H.I.V. positive.
I need your help.

Edmund White
Writer		 I'm H.I.V. positive.
And I'm worth it.

Hugh Steers
Artist
I'm H.I.V. positive.
I hope to meet more angels.

Ilka Tanya Payan
Actress, Attorney, Activist		 I'm H.I.V. positive
Going once,going twice....

Robert Woolley
Auctioneer
I'm H.I.V. positive.
I have a lot to give.

Bill T. Jones
Choreographer		 I'm H.I.V. positive.
And I'm fighting back.

Tom Duane
New York City Council Member

CRIA gratefully acknowledges the generous donation of our annual report's design by Vincent Gagliostro Studio

Board of Directors

Ross Bleckner, President Kiki Mason, Vice-President George Stathakis, Treasurer Robert Levy, Esq., Secretary Marisa Cardinale Phyllis Danilow Douglas Dieterich, MD Caio Fonseca Charles Franchino, DC Michael Goff Donald Kotler, MD Monica Lynch Paul Meier, PhD Judith Rabkin, PhD, MPH

Staff

J Daniel Stricker, Executive Director

Research Connie Abelardo, MD, Senior Research Coordinator Gloria Howard-Mello, MD, Research Coordinator Douglas Mendez, MD, Research Coordinator Raquel Sanchez, Research Technician Rick Loftus, Research Associate

Adminstration & Development Anthony McPhatter, Director of Administration J. A. Forde, Development Director Anne Corry, Director of Institutional Giving Gary Bonasorte, Volunteer/Education Coordinator Spencer Cox, CRIA Update Managing Editor

CRIA home pagestudiesupdates

cria@aidsnyc.org
Pages last modified 3/24/97
copyright CRIA © 1997

HOME